Alix Rosenberg
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Alix Rosenberg has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
- Aditya Surapaneni
Division of Precision Medicine, Department of Medicine New York University Grossman School of Medicine New York NY USA
1 shared publication Alexa R. Ellis
Northwell Health New Hyde Park New York USA
1 shared publication- Amanda Hyre Anderson
Department of Epidemiology, Tulane University School of Public Health and Tropical Medicine, New Orleans, Louisiana
1 shared publication - Ashley Rose
Lenox Hill Hospital , New York, NY 10075
1 shared publication Carina Flaherty
Division of Precision Medicine, Department of Medicine, New York University, New York, New York
1 shared publication- Celina Liu
Department of Orthopaedic Surgery, Stony Brook University Hospital, Stony Brook, New York
1 shared publication
Latest Publications
- 30 August 2026
- Published by Wiley in American Journal of Medical Genetics Part A
A Scoping Review of Pentalogy of Cantrell: Insights From a Case With IC2 Hypomethylation on Chromosome 11p15 (Beckwith–Wiedemann Syndrome Locus)
Pentalogy of Cantrell (POC) is a rare constellation of congenital differences characterized by a midline supraumbilical abdominal wall defect, lower sternal defect, deficiency of the anterior diaphragm, defect of the diaphragmatic pericardium, and congenital intracardiac anomalies. While its embryologic origins are presumed to stem from early developmental disruption, the underlying etiology remains poorly understood. To systematically map and characterize reported cases of pentalogy of Cantrell in the literature, with emphasis on clinical features, associated anomalies, genetic findings, and proposed developmental mechanisms. A scoping review of published cases of pentalogy of Cantrell was conducted using PubMed, with additional cases identified through reference lists of included articles. Eligible studies included published case reports and case series describing complete or incomplete pentalogy of Cantrell. Data were charted on study characteristics, phenotypic features, associated anomalies, genetic findings, and relevant perinatal and familial factors. In some instances, cases cited within secondary reports could not be independently verified due to lack of access to the original publications. A total of 242 cases of complete pentalogy of Cantrell and 441 cases of incomplete presentations were identified. Out of the 683 total cases, 91 cases included some form of genetic finding. Reported cases demonstrate substantial phenotypic variability, with frequent intracardiac anomalies and variable extracardiac findings. Classification was often limited by incomplete reporting, inconsistent diagnostic criteria, and restricted clinical detail. Genetic evaluations were inconsistently performed and no unifying etiology has been identified. In our novel case, features of POC were identified in association with IC2 hypomethylation on chromosome 11p15, consistent with Beckwith–Wiedemann syndrome. To our knowledge, this represents the first reported case of this association and suggests a potential epigenetic contribution. This scoping review highlights the clinical heterogeneity of POC and the limited understanding of its underlying pathogenesis. The presence of epigenetic alterations in our included case suggests that imprinting disturbances may contribute to a subset of presentations, thus warranting further investigation.
- 30 August 2026
- Published by Wiley in American Journal of Medical Genetics Part A
A Scoping Review of Pentalogy of Cantrell: Insights From a Case With IC2 Hypomethylation on Chromosome 11p15 (Beckwith–Wiedemann Syndrome Locus)
Pentalogy of Cantrell (POC) is a rare constellation of congenital differences characterized by a midline supraumbilical abdominal wall defect, lower sternal defect, deficiency of the anterior diaphragm, defect of the diaphragmatic pericardium, and congenital intracardiac anomalies. While its embryologic origins are presumed to stem from early developmental disruption, the underlying etiology remains poorly understood. To systematically map and characterize reported cases of pentalogy of Cantrell in the literature, with emphasis on clinical features, associated anomalies, genetic findings, and proposed developmental mechanisms. A scoping review of published cases of pentalogy of Cantrell was conducted using PubMed, with additional cases identified through reference lists of included articles. Eligible studies included published case reports and case series describing complete or incomplete pentalogy of Cantrell. Data were charted on study characteristics, phenotypic features, associated anomalies, genetic findings, and relevant perinatal and familial factors. In some instances, cases cited within secondary reports could not be independently verified due to lack of access to the original publications. A total of 242 cases of complete pentalogy of Cantrell and 441 cases of incomplete presentations were identified. Out of the 683 total cases, 91 cases included some form of genetic finding. Reported cases demonstrate substantial phenotypic variability, with frequent intracardiac anomalies and variable extracardiac findings. Classification was often limited by incomplete reporting, inconsistent diagnostic criteria, and restricted clinical detail. Genetic evaluations were inconsistently performed and no unifying etiology has been identified. In our novel case, features of POC were identified in association with IC2 hypomethylation on chromosome 11p15, consistent with Beckwith–Wiedemann syndrome. To our knowledge, this represents the first reported case of this association and suggests a potential epigenetic contribution. This scoping review highlights the clinical heterogeneity of POC and the limited understanding of its underlying pathogenesis. The presence of epigenetic alterations in our included case suggests that imprinting disturbances may contribute to a subset of presentations, thus warranting further investigation.
- Open Access
- 19 August 2026
- Published by Oxford University Press (OUP) in The Oncologist
- Vol. 31 (10)
RAF/MEK clamp inhibition with avutometinib and cetuximab in RAF1 S257L–mutated, anti-EGFR–refractory metastatic colorectal cancer in Gaucher’s disease
RAF1 alterations are rare in metastatic colorectal cancer (mCRC), occurring in roughly 0.5% of cases, and lack established treatment guidance. We present a patient with RAF1 S257L–mutated, RAS wild-type mCRC and concurrent type 1 Gaucher disease, whose baseline cytopenias precluded standard chemotherapy and clinical-trial enrollment. After progression on fluoropyrimidine-, oxaliplatin-, and irinotecan-based regimens (the latter with the anti-EGFR antibody panitumumab) complicated by recurrent neutropenic sepsis, he received off-label avutometinib and defactinib (an oral RAF/MEK clamp inhibitor plus a FAK inhibitor) combined with cetuximab. He achieved a radiographic response, biomarker decline, hematologic recovery, and improvement in ECOG performance status from 3 to 0, with benefit lasting approximately 6 months. At progression, circulating tumor DNA revealed persistence of RAF1 S257L at high allele fraction with RAF1 amplification, together with newly acquired EGFR ectodomain mutations, KRAS alterations, and a MAP2K1 alteration—a polyclonal pattern of convergent MAPK/EGFR reactivation. This case illustrates how a molecular tumor board can translate a rare driver into a rational, individualized regimen and how serial liquid biopsy informs resistance and next steps.
- 19 August 2026
- Published by Oxford University Press (OUP) in The Oncologist
- Vol. 31 (10)
Open AccessRAF/MEK clamp inhibition with avutometinib and cetuximab in RAF1 S257L–mutated, anti-EGFR–refractory metastatic colorectal cancer in Gaucher’s disease
RAF1 alterations are rare in metastatic colorectal cancer (mCRC), occurring in roughly 0.5% of cases, and lack established treatment guidance. We present a patient with RAF1 S257L–mutated, RAS wild-type mCRC and concurrent type 1 Gaucher disease, whose baseline cytopenias precluded standard chemotherapy and clinical-trial enrollment. After progression on fluoropyrimidine-, oxaliplatin-, and irinotecan-based regimens (the latter with the anti-EGFR antibody panitumumab) complicated by recurrent neutropenic sepsis, he received off-label avutometinib and defactinib (an oral RAF/MEK clamp inhibitor plus a FAK inhibitor) combined with cetuximab. He achieved a radiographic response, biomarker decline, hematologic recovery, and improvement in ECOG performance status from 3 to 0, with benefit lasting approximately 6 months. At progression, circulating tumor DNA revealed persistence of RAF1 S257L at high allele fraction with RAF1 amplification, together with newly acquired EGFR ectodomain mutations, KRAS alterations, and a MAP2K1 alteration—a polyclonal pattern of convergent MAPK/EGFR reactivation. This case illustrates how a molecular tumor board can translate a rare driver into a rational, individualized regimen and how serial liquid biopsy informs resistance and next steps.
- 5 November 2024
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 20 (1) , 23-30
Surrogate End Points in Apolipoprotein L1–Associated Kidney Disease
Key Points: Apolipoprotein L1 (APOL1) high-risk genotype had higher risk of 3-year GFR-related surrogate end points and long-term kidney failure than those with the low-risk genotype. No consistent difference in surrogate–clinical outcome associations by APOL1 genotype, supporting the use of surrogates in APOL1 kidney disease. Background: Surrogate end points for the clinical outcome of kidney failure have been accepted by the US Food and Drug Administration. However, they have not been specifically evaluated in Apolipoprotein L1 ( APOL1 )-associated kidney disease. Methods: This random-effects meta-analysis included Black participants in the Atherosclerosis Risk in Communities study ( N =3071), Chronic Renal Insufficiency Cohort ( N =998), and African American Study of Kidney Disease and Hypertension ( N =609). Surrogate end points included a 3-year 30% and 40% decline in GFR, doubling of urine protein–creatinine ratio, and >3 ml/min per 1.73 m 2 per year decline in GFR. Clinical outcomes included kidney failure requiring KRT, heart failure, cardiovascular disease, and death after 3 years. Results: 22% in the African American Study of Kidney Disease and Hypertension, 18% in the Chronic Renal Insufficiency Cohort, and 13% in the Atherosclerosis Risk in Communities study had the APOL1 high-risk genotype. Participants with the APOL1 high-risk genotype had higher risk of all 3-year GFR outcomes but not doubling of urine protein–creatinine ratio, as well as kidney failure after 3 years. The 3-year outcomes were strongly associated with kidney failure with weaker but statistically significant associations with the development of heart failure, cardiovascular disease, and mortality. There were no differences in associations between short-term and long-term clinical outcomes by APOL1 risk status. Conclusions: Individuals with the APOL1 high-risk genotype were more susceptible to 3-year GFR-related end points and long-term kidney failure than individuals with the APOL1 low-risk genotype. There was no consistent difference in short-term clinical outcome associations by APOL1 genotype, supporting the use of surrogates in APOL1 -associated kidney disease.
- 5 November 2024
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 20 (1) , 23-30
Surrogate End Points in Apolipoprotein L1–Associated Kidney Disease
Key Points: Apolipoprotein L1 (APOL1) high-risk genotype had higher risk of 3-year GFR-related surrogate end points and long-term kidney failure than those with the low-risk genotype. No consistent difference in surrogate–clinical outcome associations by APOL1 genotype, supporting the use of surrogates in APOL1 kidney disease. Background: Surrogate end points for the clinical outcome of kidney failure have been accepted by the US Food and Drug Administration. However, they have not been specifically evaluated in Apolipoprotein L1 ( APOL1 )-associated kidney disease. Methods: This random-effects meta-analysis included Black participants in the Atherosclerosis Risk in Communities study ( N =3071), Chronic Renal Insufficiency Cohort ( N =998), and African American Study of Kidney Disease and Hypertension ( N =609). Surrogate end points included a 3-year 30% and 40% decline in GFR, doubling of urine protein–creatinine ratio, and >3 ml/min per 1.73 m 2 per year decline in GFR. Clinical outcomes included kidney failure requiring KRT, heart failure, cardiovascular disease, and death after 3 years. Results: 22% in the African American Study of Kidney Disease and Hypertension, 18% in the Chronic Renal Insufficiency Cohort, and 13% in the Atherosclerosis Risk in Communities study had the APOL1 high-risk genotype. Participants with the APOL1 high-risk genotype had higher risk of all 3-year GFR outcomes but not doubling of urine protein–creatinine ratio, as well as kidney failure after 3 years. The 3-year outcomes were strongly associated with kidney failure with weaker but statistically significant associations with the development of heart failure, cardiovascular disease, and mortality. There were no differences in associations between short-term and long-term clinical outcomes by APOL1 risk status. Conclusions: Individuals with the APOL1 high-risk genotype were more susceptible to 3-year GFR-related end points and long-term kidney failure than individuals with the APOL1 low-risk genotype. There was no consistent difference in short-term clinical outcome associations by APOL1 genotype, supporting the use of surrogates in APOL1 -associated kidney disease.